Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CryoIT: Cryoimmunotherapy with Dendritic Cells in Prostate Cancer
NCT02423928Phase 1Completed
- Start
- May 2015
- Primary completion
- Aug 2019
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ACT2001 in castration-resistant prostate cancer (CRPC). Primary endpoints: Composite measure of the safety and toxicity profile, including definition of the Maximum Tolerated Dose at 72 weeks and Pembrolizumab tested to boost dendritic cell-based immunity at 52 weeks. Started May 2015; status: completed.
02
Drugs
ACT2001
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02423928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02423928.